To investigate the safety and efficacy of neoadjuvant chemotherapy and targeted therapy combined with surgery in patients with clinical stage Ⅲ (cⅢ) lung adenocarcinoma with EGFR mutation.

Twelve patients with cⅢ lung adenocarcinoma with EGFR mutation treated with neoadjuvant therapy and targeted therapy from September 2019 to September 2020 were selected, 10 patients completed surgery was group A, and 20 patients with cⅢ lung adenocarcinoma with EGFR mutation treated with surgery alone at the same period were selected as the control group (group B) . The clinical data were retrospectively reviewed.

Among the observation group, 1 patient had disease progression (PD) after neoadjuvant chemotherapy combined with targeted therapy, 1 patient had stable lesion (SD) and PS 3 score without surgery, and the remaining 10 patients with partial remission (PR) received surgery after chemotherapy 3-4 weeks. Postoperative pathology confirmed that the effect of adjuvant therapy was obvious (9/12) . There was no significant difference in gender, age, number of lymph node dissection and incidence of serious complications between the two groups (P>0.05) ; the average intraoperative bleeding in group A was more than that in group B, and the postoperative hospital stay was longer, but there was no significant difference (P>0.05) ; there was significant difference in tumor differentiation between the two groups (P<0.05) .

For patients with cⅢ lung adenocarcinoma confirmed by pathology, and with EGFR positive with good health (PS 0-2) , preoperative neoadjuvant chemotherapy and targeted therapy followed with surgery can reduce the preoperative clinical stage, and this new comprehensive treatment mode is safe and effective.